NASDAQ · Drug Manufacturers - General

MIRA (MIRA) Stock

$0.91 +3.15% NASDAQ: MIRA Healthcare

Valuation

MetricValue
Price$0.91
Market Cap$38.22M
P/E Ratio-0.73
P/B Ratio4.10
P/S Ratio0.00
EPS (TTM)$-1.35
52-Week High$2.45
52-Week Low$0.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.00%
ROA-90.91%
ROCE-100.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-7.0M$-9.0M$-8.0M$-10.0M
Net Profit$-2.0M$-7.0M$-12.0M$-8.0M$-10.0M
EPS$-0.15$-0.48$-0.65$-0.51$-1.35
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0M$1.0M$5.0M$3.0M$11.0M
Total Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M
Cash$3.0M$0$5.0M$3.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies MT Newswires · Jul 10, 2026 MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain ACCESS Newswire · Jul 10, 2026 Clockwork.ai Launches Mira: The AI Giving 3,000+ Businesses a CFO They Could Never Afford PR Newswire · Jul 8, 2026 Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies MT Newswires · Jul 6, 2026 MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction ACCESS Newswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-6.0M$-5.0M$-6.0M$-5.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$3.0M$-2.0M$4.0M$-2.0M$4.0M
Free Cash Flow$-1.0M$-6.0M$-5.0M$-6.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-10.46%
Quick Ratio82.16
Interest Coverage—
Return 1Y-42.77%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
APUS $5.15 +4.67% -7.51 $7.77M 0.00%
IGC $0.26 +2.68% — $25.68M 0.00%
MLSS $0.40 +3.13% -10.04 $35.59M 0.00%
MODD $2.39 +15.46% -0.22 $5.04M 0.00%

About MIRA

MIRA is led by CEO Erez Aminov, employs 2 people, headquartered in US, publicly traded since 2023.

MIRA stock trades at $0.91 with a market capitalization of $38.22M. The stock is valued at a price-to-earnings (P/E) ratio of -0.73, price-to-book of 4.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.88 and $2.45, and currently trades 62.9% below its 52-week high.

On profitability, MIRA generates a return on equity (ROE) of -100.00%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides